Cargando…

Steroid hormones regulate genome-wide epigenetic programming and gene transcription in human endometrial cells with marked aberrancies in endometriosis

Programmed cellular responses to cycling ovarian-derived steroid hormones are central to normal endometrial function. Abnormalities therein, as in the estrogen-dependent, progesterone-“resistant” disorder, endometriosis, predispose to infertility and poor pregnancy outcomes. The endometrial stromal...

Descripción completa

Detalles Bibliográficos
Autores principales: Houshdaran, Sahar, Oke, Ashwini B., Fung, Jennifer C., Vo, Kim Chi, Nezhat, Camran, Giudice, Linda C.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7299312/
https://www.ncbi.nlm.nih.gov/pubmed/32555663
http://dx.doi.org/10.1371/journal.pgen.1008601
Descripción
Sumario:Programmed cellular responses to cycling ovarian-derived steroid hormones are central to normal endometrial function. Abnormalities therein, as in the estrogen-dependent, progesterone-“resistant” disorder, endometriosis, predispose to infertility and poor pregnancy outcomes. The endometrial stromal fibroblast (eSF) is a master regulator of pregnancy success. However, the complex hormone-epigenome-transcriptome interplay in eSF by each individual steroid hormone, estradiol (E(2)) and/or progesterone (P(4)), under physiologic and pathophysiologic conditions, is poorly understood and was investigated herein. Genome-wide analysis in normal, early and late stage eutopic eSF revealed: i) In contrast to P(4), E(2) extensively affected the eSF DNA methylome and transcriptome. Importantly, E(2) resulted in a more open versus closed chromatin, confirmed by histone modification analysis. Combined E(2) with P(4) affected a totally different landscape than E(2) or P(4) alone. ii) P(4) responses were aberrant in early and late stage endometriosis, and mapping differentially methylated CpG sites with progesterone receptor targets from the literature revealed different but not decreased P(4)-targets, leading to question the P(4)-“resistant” phenotype in endometriosis. Interestingly, an aberrant E(2)-response was noted in eSF from endometriosis women; iii) Steroid hormones affected specific genomic contexts and locations, significantly enriching enhancers and intergenic regions and minimally involving proximal promoters and CpG islands, regardless of hormone type and eSF disease state. iv) In eSF from women with endometriosis, aberrant hormone-induced methylation signatures were mainly due to existing DNA methylation marks prior to hormone treatments and involved known endometriosis genes and pathways. v) Distinct DNA methylation and transcriptomic signatures revealed early and late stage endometriosis comprise unique disease subtypes. Taken together, the data herein, for the first time, provide significant insight into the hormone-epigenome-transcriptome interplay of each steroid hormone in normal eSF, and aberrant E(2) response, distinct disease subtypes, and pre-existing epigenetic aberrancies in the setting of endometriosis, provide mechanistic insights into how endometriosis affects endometrial function/dysfunction.